bioAffinity Technologies (BIAF) Short term Debt (2022 - 2023)

bioAffinity Technologies (BIAF) posted quarterly Short term Debt of $42334.0 for Q2 2023, down 74.87% quarter-over-quarter from $168430.0 in Q1 2023.

bioAffinity Technologies (BIAF) Short term Debt (2022 - 2023) Analysis & Trends

bioAffinity Technologies (BIAF) has reported Short term Debt for 2 consecutive years, with $42334.0 the latest figure, recorded in Q2 2023.

In Q2 2023, Short term Debt changed N/A year-over-year to $42334.0; the TTM figure through Jun 2023 stood at $42334.0 (changed N/A YoY), while the FY2022 annual figure was $251746.0, changed N/A from the prior year.
Short term Debt declined to $42334.0 in Q2 2023 per BIAF's latest filing, from $168430.0 in the prior quarter.
Across five years, Short term Debt topped out at $500000.0 in Q3 2022 and bottomed at $42334.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	213.88 Bn	209.81 Bn	8.34 Bn
2	Danaher	140.65 Bn	136.30 Bn	3.61 Bn
3	Idexx Laboratories	46.02 Bn	45.83 Bn	779.09 Mn
4	Agilent Technologies	39.85 Bn	38.05 Bn	990.00 Mn
5	Iqvia Holdings	39.20 Bn	37.12 Bn	1.44 Bn
6	Natera	38.80 Bn	37.70 Bn	696.04 Mn
7	Illumina	30.11 Bn	28.94 Bn	770.00 Mn
8	Mettler Toledo International	28.66 Bn	28.61 Bn	650.22 Mn
9	Quest Diagnostics	26.24 Bn	25.61 Bn	1.03 Bn
10	bioAffinity Technologies	2.38 Mn	-721,990.64	-

Download Data